Plain-English translation of NCT06515613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called , which is an antibody designed to target cancer cells that express a protein called claudin-6. The trial is enrolling people with platinum-resistant ovarian cancer, testicular cancer, and endometrial cancer to see if the medication is safe and how well it works. Researchers will start with lower doses and gradually increase them to find the best dose for treating cancer.
Platinum-resistant ovarian cancer and other advanced solid tumors are difficult to treat because cancer cells become resistant to standard chemotherapy. This trial exists to evaluate whether this new treatment can help patients whose cancers have stopped responding to conventional options.
You likely qualify if…
You likely don't qualify if…
In the first part of the trial, you would receive a single dose of the medication and be monitored closely for 28 days to check for side effects and how your body responds. If the dose is well-tolerated, the trial moves into a second phase where more participants receive the medication at different dose levels to find the best treatment dose. Throughout the trial, you will have regular clinic visits, blood tests, and imaging scans to track your cancer and monitor your health until your disease progresses or you and your doctor decide to stop.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States